Investor Presentation September 30, 2025 CAUTIONARY STATEMENT This document is current as of September 30, 2025, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be reli ...

BOCA RATON, Fla., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announces that in order to assist the Company in managing near-term working capital requirements, the Company and Jim Cacioppo, the Company’s Chairman and Chief Executive Officer, have agreed to certain amendments to Mr. Cacioppo’s employment agreement (collectively, the “Employment Agreement Amendments”). All of the Employment ...

All right, welcome back to Worldwide Exchange. As we close on the 6 a. m.hour, a check of a few big stories that we're following this morning. The US says it collected more than $200 billion in tariffs this [music] year, according to new data from Customs and Border Protection. The figure comes as a [music] Supreme Court weighs the legality of those duties.President Trump's filing a $10 billion defamation lawsuit against the BBC. The president [music] is accusing the British broadcaster of producing a false ...

Core Insights - Organigram Global Inc, Canada's leading recreational cannabis company, reported record financial results for the fourth quarter and fiscal year ending September 30, 2025, highlighting significant growth in revenue and market share [2][4]. Fiscal 2025 Financial Highlights - Gross revenue reached $403.0 million, a 63% increase year-over-year, while net revenue was $259.2 million, up 62% from the previous year [4][6]. - Adjusted EBITDA increased by 160% to $21.9 million, driven by higher recreational cannabis revenue and improved gross margins [4][6]. - The company maintained a 11.9% market share in the Canadian recreational cannabis market [4][6]. Fourth Quarter 2025 Financial Overview - In Q4, gross revenue was $123.3 million, a 76% increase year-over-year, with net revenue rising 79% to $80.1 million [4][6]. - Adjusted gross margin for Q4 was $30.6 million, representing 38% of net revenue, compared to 37% in Q4 Fiscal 2024 [4][6]. - The net loss for Q4 was $38.0 million, a significant increase from a loss of $5.4 million in the same quarter last year, primarily due to non-cash changes in fair value [4][6]. Strategic Initiatives and Acquisitions - The company expanded its capabilities through acquisitions, including Motif Labs Ltd., enhancing its extraction capabilities and market presence [2][4]. - Organigram launched its Fast Acting Soluble Technology (FAST) and entered the U.S. cannabinoid beverages market through the acquisition of Collective Project Limited [4][12]. - The company is focused on operational scale, intellectual property, and market access to support future growth [2][4]. International Growth - Record international revenue reached $26.3 million, a 173% increase year-over-year, reflecting the company's expanding global footprint [4][12]. - The company completed its EU-GMP audit and is awaiting certification confirmation, which will facilitate further international expansion [12][4]. Balance Sheet and Liquidity - As of September 30, 2025, the company had cash, restricted cash, and short-term investments totaling $84.4 million, down from $133.4 million the previous year [9][10]. - Total assets increased by 37% to $562.2 million, while total liabilities rose by 109% to $213.1 million [10][9]. Future Outlook - The company anticipates strong revenue growth in Fiscal 2026, with net revenue expected to exceed $300 million, supported by increasing domestic and international demand [7][4].

Core Viewpoint - President Trump is considering reclassifying marijuana from a Schedule I to a Schedule III drug, which could significantly impact the cannabis industry and research opportunities [1][6][10]. Industry Impact - Reclassifying marijuana as a Schedule III drug would ease the buying and selling of cannabis, potentially increasing profitability for the cannabis industry [6][7]. - The reclassification would lower barriers to research, allowing for more extensive studies on marijuana [2][6]. - Cannabis stocks surged following reports of Trump's consideration to ease federal restrictions on marijuana [9][12]. Legislative Context - The Biden administration had previously pursued reclassification but did not implement changes before Trump left office [15]. - Various bills have been introduced in Congress to lower marijuana's classification or decriminalize it, but none have been signed into law [15]. Public Sentiment and Political Commentary - Senator Ron Wyden criticized Trump for misleading the public regarding the legality of marijuana, emphasizing that reclassification does not equate to decriminalization [10][11].

Core Viewpoint - Canopy Growth Corporation is making strategic moves to strengthen its position in the cannabis industry, particularly through the acquisition of MTL Cannabis Corp, while facing current stock price challenges [1][2][3]. Company Overview - Canopy Growth Corporation, listed on Nasdaq as CGC, is a significant player in the cannabis sector, involved in the production and sale of cannabis products for both medical and recreational markets [1]. - The company's current stock price is $1.66, reflecting a decrease of approximately 4.89% [3]. Recent Developments - Alliance Global Partners has adjusted its rating for Canopy Growth to Neutral and raised the price target from C$2 to C$2.50 following the announcement of the acquisition of MTL Cannabis Corp [2]. - The acquisition involves obtaining all issued and outstanding common shares of MTL Cannabis and settling associated debts, positioning Canopy Growth as a leading medical cannabis business in Canada [2]. Market Performance - Canopy Growth's stock has experienced significant volatility over the past year, with a high of $3.14 and a low of $0.77, and currently has a market capitalization of approximately $396.8 million [4]. - Today's trading volume for CGC is notably high, with 101,136,052 shares exchanged on the NASDAQ exchange [4].

The legal status of marijuana in the U.S. remains scattered and confusing.A sharp pull-back in marijuana stocks dinged the value of Tilray Brands (TLRY 10.04%) shares on Monday. At the end of last week, investor hopes rose that President Donald Trump would take an important step toward the de facto legalization of the drug, but those hopes didn't materialize on Monday. Investors eagerly sold out of Tilray, leaving the stock with a 10% loss that trading session. Awaiting a signaturePot stock bulls came out i ...

Core Viewpoint - President Trump is considering an executive order to reclassify marijuana as a Schedule III substance, which could significantly impact the cannabis market and facilitate scientific research [1][3]. Market Reaction - Cannabis stocks experienced a pullback as investors took profits after a rally of 30% to 40% in companies like Canopy Growth Corp., SNDL Inc., and Tilray Brands, Inc. following initial reports of the potential reclassification [4]. - The reclassification could lead to a major shift in national drug regulations, aligning cannabis with standard pharmaceuticals and allowing financial institutions to engage with the sector [4]. Financial Implications - Reclassification is expected to reduce tax burdens and improve access to capital for cannabis companies, which currently face challenges in obtaining financing due to national bans [5]. Background & Next Steps - Although no official decision has been made regarding the scheduling change, the process is in motion, with the Drug Enforcement Administration having the final authority on the regulatory switch [6].

Cannabis Industry & Tilray Brands - Tilray Brands anticipates potential rescheduling of marijuana to schedule three drug by President Trump, which would reduce federal restrictions [1][3] - Rescheduling would allow Tilray to enter the US market, leveraging research and clinical studies from Canada and Europe, focusing on medical cannabis [5] - Tilray aims to collaborate with the FDA, hospitals, and doctor groups to provide cannabis for medical purposes, such as cancer, epilepsy, stress, and sleep [5][6] - Tilray has over 6 million square feet of cannabis grow space in Canada and Europe, planning to bring strains and genetics to the US [6] - Tilray estimates a potential US medical cannabis market of $10 billion, with a target of 3% to 10% market share, translating to a $300 million to $1 billion business [8] - Tilray has a $50 million business selling cannabis drinks in Canada, and sees potential opportunities in the US with regulated hemp THC products [14] Market Trends & Economic Data - S&P 500 equal weighted index has been outperforming recently, up about 3% in the last month [22] - Healthcare sector (XLV) is the best performing sector this quarter, up 12%, while financials are up about 2% [24] - Crude oil settled at the lowest point in four years at $5665 per barrel, down about 20% this year, while energy sector is up about 5% year-to-date [29][30] - Bitcoin is down 22% year-to-date, with shorts in control and a washout point at $75,000 [33] Women in the Workplace - A McKenzie report indicates a gap between men and women in seeking promotions in corporate environments [36] - A study indicates 86% of senior women leaders are more ambitious than five years ago, seeking flexibility, autonomy, and control [37] - 89% of women queried said they've made a massive change in the last few years, with 71% of those women making that decision by choice [40]

Company Overview - iRobot, the maker of Roomba, has filed for bankruptcy and plans to hand over control to its main Chinese supplier, expecting to complete Chapter 11 by February [1] - Founded in 1990, iRobot has sold over 40 million Roomba units since its launch in 2002, but has faced declining earnings due to supply chain issues and competition from cheaper alternatives [2][3] Financial Performance - iRobot's shares have dropped more than 80% as a result of its financial struggles [1] - The company received over $90 million in compensation from a failed acquisition deal with Amazon, but much of this was used to cover advisory fees and loan repayments [3] Industry Competitors - The stock prices of major tech companies like Nvidia and Tesla have seen slight rebounds, with Nvidia's shares up more than 1% despite recent declines [4] - Concerns about competition from Google's tensor processing units have negatively impacted Nvidia, which has fallen more than 6% over the past month [5] Mergers and Acquisitions - Intel is reportedly in advanced talks to acquire AI startup Samba Nova Systems for approximately $1.6 billion, which could enhance its product offerings [6] - The connection between Intel and Samba Nova is significant, as Intel's CEO is also the chairman of Samba Nova [7] Cannabis Industry - Canopy Growth's shares have surged over 50% following its announcement to acquire Metal Cannabis, valued at about 125 million CAD [8] - Other cannabis companies like Tilray Brands have also seen stock increases, with Tilray up about 4% due to ongoing discussions about drug classification changes [9]